June 15, 2017
Session 1: Chairs: Daniel Monakier, Willmosh Marmerstein
Erbb2 Triggers Mammalian Heart Regeneration by Promoting Cardiomyocyte Dedifferentiation and Proliferation
Alla Aharonov, Weizmann Institute
Predicting Chemotherapy Induced Cardiomyopathy Using Pluripotent Stem Cells
Oren Caspi, Cardiology Department, Rambam Health Care Campus
Cardiovascular Disease Prevention in Adult Cancer Survivors?
Robert Klempfner, Sheba Medical Center
 Pregnancy After Cardio-Toxic Cancer Therapy
Sorel Goland, Kaplan Medical Center, Rehovot
 Session 2: Chairs: Pia Raanani, Rinat Yerushalmi, Moti Vaturi
Breast Cancer in 21st Century: Is cardiotoxicity still an issue?
Karen Gelmon, BC Cancer Center, Vancouver, BC, Canada
Modern CML therapy links to cardiovascular systemTristan Mirault, Vascular Medicine , Hôpital européen Georges Pompidou

Université Paris Descartes, France

Development of First Nano-Drug for Cancer Therapy with Heart Safety in Mind: Doxil Story by the Developer
Tamar Safra, Ichilov, Tel Aviv
Thrombosis and Thromboprophylaxis in Cancer Patient
Galia Spectre, Rabin Medical Center, Petah Tikva
Use of advanced Echo-Imaging in Cardio-Oncology
Shemy Carasso, Poriah Medical Center, Tiberias
 Session 3: Chairs: Bella Kaufman, Livia Kapusta
Tailoring Evidence-Based Cardiology for Cancer Patients: Urgent Need for Randomized Controlled Trials
Dan Lenihan, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Current Evidence that Cardiovascular Disease and Malignancy are Synergistic
Zaza Iakobishvili, Rabin Medical Center, Petah Tikva
Pathophysiology of malignancy: links to cardiovascular system
Tal Hasin, Shaare Zedek, Jerusalem, Israel
Sometimes It’s Just a Matter of the Heart – AshSometimes It’s Just a Matter of the Heart - Elnekave
Shifra Ash /Eldad Elnekave, Schneider Children’s Medical Center of Israel
 Session 4: Chairs: Victoria Neiman, Tuvia Ben Gal
“Cardiovascular Risk Assessment and Management in Anthracycline Therapy for Hematologic Cancers: Cardioxan is Still Relevant: PRO
Israel Gotsman, Hadassah Heart Institute, Jerusalem
CON
Anat Gafter, Rabin Medical Center, Petah Tikva, Israel
Acute Anthracycline Induced Cardiotoxicity in Patient with Acute Myeloid Leukemia Undergoing Allogeneic Transplant following Induction Therapy
Oren Pasvolsky, Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center
Cardiovascular Risk Assessment and Management in Prostate Cancer Treated by Androgen Deprivation Therapy
David Sarid, Institute of Oncology, Tel Aviv Sourasky Medical Center
Radiation and the heart: Is it still issue with modern radiotherapy protocols?
Eyal Fenig, Davidov Cancer Center, Rabin Medical Center, Petah Tikva
How to Manage Implanted Electrophysiology Devices in Cancer Patient Undergoing Radiotherapy
Ehud Kadmon, Rabin Medical Center
June 16, 2017 
Session 5: Chairs: Yehuda Adler, Nir Peled
Joint Session with ESC Working Group on Myocardial and Pericardial Diseases: Cardiac amyloidosis, case-based presentation
Arthur Pollak, Hadassah Heart Institute, Jerusalem
Multiple Myeloma – cardiovascular implications of treatment
Michael Arad, Leviev Heart Center, Sheba, Tel Hashomer
Cancer Patient with Pulmonary Hypertension: case presentation and discussion
Avi Shimony, Soroka Medical Center, Beer Sheva
Biomarkers in Cardio-Oncology: beyond troponins (NPs, IgE, inflammatory compounds)
Yeela Talmor Barkan, Department of Cardiology, Rabin Medical Center, Petah Tikva
 Session 6: Chairs: Dan Gilon, Eliahu Gez
Nuclear Imaging in Cardio-Oncology: What’s New?
Ashraf Hamdan, Rabin Medical Center, Petah Tikva, Israel
Cancer Patient with Chest Pain
Chaim Lotan, Heart Institute, Hadassah Medical Center, Jerusalem
5-FU associated acute coronary syndrome: how to manage?
Michal Laufer-Perl, Ichilov, Department of Cardiology, Tel Aviv, Israel
Cancer Immunotherapy: Safe for the Heart?
Ido Wolf, Ichilov, Tel Aviv Medical Center, Tel Aviv, Israel